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Background: Adiponectin is an adipokine with insulin-sensitizing effects. We investigated the relationship between
the single nucleotide polymorphism (SNP) +45 T > G ( rs 2241766 ;Gly15Gly) in the adiponectin gene, serum
adiponectin levels, insulin resistance and risk of gestational diabetes (GDM) in Iranian population.
Methods: 65 GDM patients and 70 healthy pregnant women were enrolled in this study. Genotyping for SNP +45
T > G in the adiponectin gene ( rs 2241766 ) was performed by the polymerase chain reaction-restriction fragment
length polymorphism method. The level of fasting serum adiponectin, insulin, glucose, and lipid levels were measured.
Insulin resistance was estimated using homeostasis model of assessment for insulin resistance (HOMA-IR).
Results: The G allele and TG/GG genotype of rs 2241766 were more frequent than the T allele and TT genotype in GDM
patients compared to the controls (p < 0.05). Multiple logistic regression analysis revealed that the risk of GDM was
significantly higher in subjects with the TG/GG genotype to those with TT genotype [odds ratio = 2.38, 95% CI 1.09-5.22,
p = 0.030]. No significant association was observed between genotypes of rs 2241766 and circulating concentrations of
adiponectin. Multiple regression analysis showed that serum adiponectin levels was negatively associated with HOMA-IR
in GDM patients (β = −0.385, p <0.01).
Conclusion: The findings demonstrated that TG/GG genotype of rs 2241766 was an independent risk factor of
GDM in our population. Furthermore, circulating adiponectin level was negatively correlated with insulin resistance
in GDM patients.
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Gestational diabetes mellitus (GDM) is a form of glucose
intolerance first diagnosed during pregnancy [1]. The
prevalence of GDM in the Iranian population is 4% to
9% of pregnancies [2]. GDM is associated with increased
risk of preeclampsia, cesarean section and developing
diabetes type 2 (T2D) for the pregnant women, macro-
somia and perinatal mortality for the fetus, and brachial
plexus injury and hypoglycemia for the neonate [3].
GDM and T2D are multifactorial disorders in which both
genetic and non-genetic factors are involved in disease sus-
ceptibility and severity. A variety of risk factors including
ethnicity, genetics, family history, lifestyle, diet and physical* Correspondence: takhshid2001@yahoo.co.uk
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unless otherwise stated.inactivity contribute to the likelihood of developing both
T2D and GDM [4]. Obesity is a common risk factor of both
T2D and GDM. Obesity could lead to the development of
insulin resistance. Many biochemical mediators are sug-
gested to correlate obesity and insulin resistance. Some of
these biomarkers are synthesized in the adipose tissue and
secreted in the circulation. Leptin, visfatin, resistin and adi-
ponectin are among these mediators [5].
Adiponectin is an adiopkine produced and secreted by
adipose tissue. It is involved in regulation of carbohydrate
and fatty acid metabolism [6,7]. In addition, it ameliorates
inflammation and prevents atherosclerosis [8]. Circulating
concentrations of the adiponectin are affected by multiple
factors including gender, age and lifestyle [9,10]. It has
been shown that circulating adiponectin concentration de-
creases in T2D, insulin resistance and obesity [11,12].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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to the circulating adiponectin concentration in GDM [13-18].
ADIPOQ gene which encodes adiponectin is located
on chromosome 3q27. This genomic region has revealed
strong linkage to insulin resistance and T2D, suggesting
that ADIPOQ is a candidate gene for T2D [19]. Several
single nucleotide polymorphisms (SNPs) at this locus
have been reported, individually or in combination as
haplotypes, to be associated with T2D, insulin resistance
and obesity in various populations. Studies have focused
mostly on SNPs rs17300539 (−11391G > A) and rs266729
(−11377 C >G) in the promoter region, rs 2241766
(Gly15Gly, +45 T >G) in exon 2 and rs1501299 (+276
G > T) in intron 2. These four variants are located within
the two adiponectin linkage disequilibrium (LD) blocks:
block 1, comprising the promoter sequence spanning the
region −14811 to −4120, and block 2, encompassing the
exons in the region −450 to +4545. The results of these
studies have been controversial with regard to whether
variability at this locus has an impact on metabolic pheno-
types of T2D and which polymorphisms are responsible
for such an effect [20]. SNP +45 T >G is a synonymous
mutation (GGT→GGG, Gly15Gly) at exon 2. Yang et al.
[21] showed that SNP +45 T >G may affect expression of
adiponectin by affecting RNA splicing and stability. The
literature reveals that the G allele of SNP +45 T >G in the
adiponectin gene has an association with obesity, insulin
resistance and T2D in several populations even though
the findings have been controversial [20].
Recently, very few studies have investigated the associ-
ations of SNP +45 T > G in the adiponectin gene with
GDM. The results of these studies were controversial
with regard to the impact of this polymorphism on the
risk of GDM and on its associations with metabolic
characteristic of GDM [22-24]. One of the reasons of
such controversy might be ethnicity as the studies con-
ducted on the Malaysian and Qatari subjects showed the
association of G allele of SNP +45 T > G in the adipo-
nectin gene with the risk of GDM, while in another
study carried out on Greek population the results did
not reveal such an association. In addition, the previous
studies demonstrated different results with respect to
the impact of SNP + 45 T > G in the adiponectin gene
on circulating level of adiponectin, obesity and insulin
resistance. Therefore, we aimed to evaluate the possible
association between the SNP +45 T > G in the adiponec-
tin gene and circulating total adiponectin levels with the
risk of GDM, obesity and insulin resistance in Iranian
pregnant women.
Methods
A sample of 135 unrelated Iranian pregnant women was
enrolled as the study group. The pregnant women were
classified as non-diabetic control group (N = 70) or havingGDM (N= 65) according to the results of oral glucose tol-
erance test (OGTT). The GDM diagnosis was performed
based on American Diabetes Association 2009 criteria, be-
tween the 24-28th week of gestation [25]. Maternal BMI
(kg/m2) was calculated as the ratio of the weight (kg) to
the squared height (m). The absence of family history for
the T2D, absence of clinical evidence of any major disease
and absence of medication use that may alter glucose tol-
erance were inclusion criteria for the control pregnant
women. The inclusion criteria for the pregnant women
with GDM were [1]: newly diagnosed cases [2], no previ-
ous use of oral hypoglycemic agents. The exclusion criteria
of the study were the presence of type-1 or type-2 diabetes
mellitus and other known major diseases. The study
protocol was approved by the ethics committee at Shiraz
University of Medical Sciences, Shiraz, Iran. Informed
written consent was obtained from all the participants.
Biochemical determinations
Fasting venous maternal blood sample was collected in
both groups, after an overnight 12- hour-fasting between
8:30 and 9:30 am. The sera were separated immediately
and stored at −70°C until biochemical analyses were per-
formed. Fasting blood glucose (FBG), total cholesterol
(TC), triglyceride (TG) and high-density lipoprotein chol-
esterol (HDL-C) were measured by using commercially
available kits. Fasting plasma low-density lipoprotein
cholesterol (LDL C) was calculated using the formula of
Friedewald. HbA1C was measured by ion-exchange high
performance liquid chromatography. Serum insulin con-
centration was measured by radioimmunoassay applying
available commercial kits. Serum total adiponectin level
was measured by the immunoassay method using a com-
mercially human adiponectin ELISA kit (Biovendor, Czech
Republic) according to the manufacturer’s instructions.
The lowest detectable level of serum adiponectin was
0.5 μg/ml and intra- and inter-assay coefficients of vari-
ation were 4.2% and 9.5%, respectively.
Insulin resistance and sensitivity indices
In this study, we used the QUICKI (quantitative insulin
sensitivity check index) model and HOMA-IR (homeostasis
model of assessment for insulin resistance) for the evalu-
ation of insulin sensitivity. These models were correlated
with direct measurement of insulin sensitivity using
the euglycemic-hyperinsulinemic clamp and validated for
evaluation of insulin sensitivity in GDM. The QUICKI
was calculated by the following formula: 1/ (log [fasting
insulin] + log [fasting glucose]). HOMA-IR is defined as
follows: ([fasting glucose] × [fasting insulin])/22.5 [26].
SNP 45 T/G genotyping
Genomic DNA was extracted and stored at −70 C prior to
polymerase chain reaction (PCR). Genotyping for detection
Table 1 Demographic characteristics and biochemical
measurements in the GDM patients and Non- GDM
subjects
Non GDM




Maternal age(y) 28.4 ± 3.7 29.2 ± 3.1 0.24
Gestational age (week) 29.3 ± 3.2 29.8 ± 3.4 0.55
BMI(Kg/m2) 27.6 ± 3.7 29.0 ± 5.0 0.12
FPG(mg/dl) 78 ± 12 91 ± 27 0.002
HbA1C (%) 5.1 ± 0.4 5.8 ± 1.0 <0.001
Insulin( μIU/ml) 16.3 ± 6.7 18.4 ± 13.1 0.33
HOMA- IR 3.2 ± 1.4 4.2 ± 3.1 0.036
QUICKI 0.33 ± 0.03 0.32 ± 0.03 0.15
TG(mg/dl) 264 ± 91 258 ± 82 0.73
TC(mg/dl ) 240 ± 53 221 ± 50 0.08
HDL-C(mg/dl ) 52 ± 12 50 ± 11 0.28
TG/HDL 5.4 ± 2.4 5.6 ± 2.6 0.66
LDL-C(mg/dl ) 120 ± 27 111 ± 29 0.13
Adiponectin (μg/ml ) 13.3 ± 7.4 12.5 ± 5.6 0.59
BMI: body mass index. FPG: fasting plasma glucose. HbA1c: hemoglobin A1c.
HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein
cholesterol. HOMA-IR: homeostasis model assessment index for insulin resistance.
QUICKI: quantitative insulin sensitivity check index. Values are presented as
mean ± SD. Student- t test was used for comparing data between groups.
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using PCR-RFLP (restriction fragment length polymor-
phisms) method. In brief, a DNA fragment corresponding
to the Adipo45T/G was amplified by forward primer (5′–
GAAGTAGACTCTGCTGAGATGG–3′) and reverse pri-
mer (5′–TATCAGTGTAGGAGGTCTGTGATG–3′). For
PCR reactions 0.4 μM of each primer were combined with
50 ng of DNA, 0.25 mM dNTPs,1.5 mM of MgCl2, and 1.0
U Taq DNA polymerase (Cinagene, Iran) in total volume of
25 μl. PCR thermal cycling was started with initial denatur-
ation at 95°C for 5 min, followed with 35 cycles of amplifi-
cation which included denaturation at 95°C for 30 sec,
annealing at 58°C for 30 sec, extension at 72°C for 30 sec,
and final extension at 72°C for 10 min. PCR products were
digested by SmaI restriction enzyme (Fermentas Life Sci-
ences, Lithuania) and separated on 2% agarose gel electro-
phoresis. The TT homozygous genotype was marked by a
single 372 bp (undigested) fragment, TG heterozygous
genotype was digested into 3 fragments of 372 bp, 209 bp
and 163 bp, and GG homozygous genotype was digested
into 2 bands of 209 bp and 163 bp . In order to evaluate
the reproducibility of the genotyping procedure, duplicate
genotyping reactions were performed on 10% of the sam-
ples.Genotyping success rate was >99%.
Statistical methods
All statistical analyses were performed using SPSS 15.0 soft-
ware (SPSS Inc., Chicago, IL, USA). The normal distribution
of variables was assessed by the Shapiro–Wilk test. Student’s
t-test and Mann–Whitney U-test were used to compare the
normally distributed and not normally distributed variables,
respectively. The data were presented in mean ± standard
deviation (SD) or ratio and percent. Multiple stepwise linear
regression analysis was conducted to assess the association
of serum adiponectin and biochemical and demographic
variables. The differences across various continuous param-
eters of adiponectin tertiles were computed using analysis of
variance (ANOVA). χ2 test was used to compare the fre-
quencies of allele and genotypes. Logistic regression analysis
was used to examine the independent association of the
SNP +45 T >G in the adiponectin gene with GDM. Con-
founding variables including maternal BMI, maternal age,
and maternal HOMA-index were included in the model.
Multivariate analysis controlling for the potential con-
founders including age, and HOMA-ir was used to compare
the means of circulating adiponectin and BMI between
different genotypes of rs 2241766. For all comparisons,
p < 0.05 was considered as statistically significant.
Results
Comparison of baseline characteristics between subjects
with and without GDM
The baseline demographic and serum biochemical mea-
surements of patients with GDM and age-matched healthypregnant women are shown in Table 1. As seen in Table 1,
there were no significant differences between demographic
characteristics of GDM and non-GDM subjects. Insulin
resistance index (as assessed by HOMA-IR) (P < 0.05),
FPG (P < 0.01) and HbA1C (P < 0.001) were higher in
GDM patients compared to non-GDM subjects. Circulat-
ing adiponectin concentration was similar in the GDM
group (12.5 ± 5.6, ranged from 4.6 to 28.6 μg/ml) and non-
GDM subjects (13.3 ± 7.4, ranged from 2.5 to 27.0 μg/ml).
Blood lipids concentrations were also similar in GDM and
non-GDM subjects. Serum insulin levels tended to be
higher in the GDM subjects compared with the non-
GDM ones, but it was not statistically significant.
Correlation between serum adiponectin and clinical
parameters
Pearson and Spearman correlation analysis showed that cir-
culating total adiponectin concentration had a negative
correlation with age (r = −0.293; p < 0.03), BMI (r= −0.288;
p= 0.032), HOMA (r=−0.353; p=0.011) and TG (r=−0.277;
p = 0.038). Conversely, adiponectin showed a positive rela-
tionship with HDL cholesterol (r = 0.311; p = 0.022). A
stepwise multiple regression model was then applied and
the results revealed that HOMA-ir and age (P < 0.009 and
P < 0.022, respectively) were independent predictors of cir-
culating adiponectin. HOMA-ir accounted for 12.4% of
the variance, whereas 10.9% was obtained for age. The
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the regression model (Table 2).
The relationship between adiponectin tertiles and vari-
ous biochemical characteristics has been shown in
Table 3. GDM patients with lowest serum adiponectin
tertile (<9.3 μg/ml) had a significantly higher serum in-
sulin concentration and HOMA-IR in comparison with
those who were in the second tertile (9.3-13.9 μg/ml)
and third tertile (<13.9 μg/ml) (P < 0.05). They also had
a lower HDL- cholesterol level and QUICKI (P < 0.05)
(Tables 3). No significant difference was found between
second tertile and third tertile groups.
Genotype and allele analysis
The genotype and allele frequencies in the non-GDM
subjects are shown in Table 4. Genotype distributions of
SNP +45 T >G in the adiponectin gene for both GDM and
non- GDM subjects did not deviate from Hardy-Weinberg
equilibrium (p <0.05). The findings showed that there was a
significant association between genotypes and alleles of
SNP 45 T/G and GDM. The GT genotype (p = 0.012, odds
ratio = 2.55, 95% CI; 1.21-5.37) and G allele (p = 0.025, odds
ratio = 2.13, 95% CI 1.09- 4.15) were more common in the
GDM patients compared to the non-GDM group (Table 4).
Logistic regression analysis was conducted to examine
whether the SNP +45 T >G was independently associated
with GDM. The findings showed that subjects with the
G-allele of SNP +45 T >G compared to subjects with TT
genotype had 2.55-fold higher risk for GDM (odds ratio =
2.55, 95% CI; 1.21-5.37, p = 0.013). The results remained
significant when confounding factors including BMI, age
and HOMA-index of mothers entered the model (odds
ratio = 2.38, 95% CI; 1.09-5.22, p = 0.030).
Effect of SNP +45 T > G in the adiponectin gene on
circulating adiponectin concentrations and BMI
In multivariate analysis which was controlled for the poten-
tial confounders including age, and HOMA-ir, no signifi-
cant differences were observed in genotypes of SNP +45Table 2 Multiple regression analysis with stepwise
analysis for serum adiponectin levels as dependent
variable
Parameters Model 1 Model 2
BMI (Kg/m2) -0.132(0.468) -0.163(0.345)
TG (mg/dl ) -0.245(0.101) -0.144(0.348)
HDLC (mg/dl ) 0.227(0.145) 0.083(0.622)
Age (year) —————— -0.330(0.024)*
HOMA-ir -0.353(0.022)* -0.385(0.009)*
R2 0.124 0.233
Data are β (P value). Parameters from model 1 and model 2 includes BMI(Kg/m2),
triglyceride(TG), HDL cholesterol(HDLC), HOMA-ir, In model 2, age of patients was
added to the parameters of the model 1. R2, multiple coefficient of determination;
β, standard correlation. In each model, all patients were included.T>G with respect to BMI (TT = 28.6 ± 4.9, GT/GG =
29.6 ± 5.5 Kg/m2, p = 0.77) and circulating concentrations
of total adiponectin (TT = 13.1 ± 4.7, GT/GG= 11.7 ±
6.4 μg/ml, p = 0.57).
Discussion
This study was performed to evaluate the possible associ-
ation between the +45 T >G (rs2241766) in the ADIPOQ
gene, circulating adiponectin level, insulin resistance, and
metabolic characteristics of GDM in Iranian population.
The findings demonstrated that the GT/GG genotype and
G-allele of SNP +45 T >G in the adiponectin gene were
more frequent in the GDM patients than in the non-
GDM subjects. The results also revealed that HOMA-ir
and age are independent predictors of serum adiponectin
levels in the GDM patients. To the best of the re-
searchers’ knowledge, this is the first study that has
been conducted on the Iranian population in which the
association of SNP +45 T > G in the ADIPOQ gene with
GDM was addressed.
The results of previous studies show ethnic variations
in allelic and genotypic frequencies of SNP +45 T > G in
the adiponectin gene [20]. In this study, the frequency of
TG/GG genotype and G allele among the non-GDM
subjects was approximately 23% and 11%, respectively
which is in line with Namvaran, et al.’s findings [27].
The frequency of the rare G allele observed in the con-
trol group of this study is similar to that reported for the
healthy subjects in some other populations [see for re-
view 31] but it is lower than that reported for the
healthy Chinese and Korean subjects (30% and 20%, re-
spectively) [28,29].
The association of SNP +45 T >G in the adiponectin
gene with T2D and insulin resistance has extensively been
investigated in several populations including the Iranian
ones There is no consistency among these studies; how-
ever, more studies have indicated that SNP +45 T >G in
the adiponectin gene is associated with insulin resistance
and T2D [20].The association of adiponectin gene poly-
morphisms and GDM has been evaluated in recent studies
[22-24] and controversial results have been obtained. With
regard to the association of SNP +45 T >G in the adipo-
nectin gene with risk of GDM, the findings of logistic re-
gression analysis showed that the risk of GDM was 2.5
fold higher in the subjects with GT/GG genotype of SNP
+45 T >G in the adiponectin gene compared to those with
TT genotype. This association remained, even after adjust-
ing for confounding factors including maternal age, insu-
lin resistance index and HbA1c. These results are
consistent with Low et al.’s study which was conducted on
a Malaysian population [22]. The current study did not
show any association between SNP +45 T >G in the adi-
ponectin gene and circulating adiponectin which is incon-
sistent with the findings of Low et al.’s study [22]. They
Table 3 Relationship between serum adiponectin tertiles and various biochemical characteristics in the GDM patients
Tertile 1(< 9.3) Tertile 2 (9.3-13.9) Tertile3 (>13.9) P values
T1 V T3Mean ± SD 95%CI Mean ± SD 95%CI Mean ± SD 95%CI
Age(y) 29.9 ± 2.6 28.3- 31. 6 29.6 ± 3.1 27.4- 30.1 28.2 ± 2.7 27.1- 30.3 0.134
Gestational age(week) 30.1 ± 3.9 27.6- 32.5 29.7 ± 2.7 28.5- 31.5 29.5 ± 3.9 27.0- 31.3 0.673
BMI(Kg/m2) 31.4 ± 3.9 27.6- 35.2 28.4 ± 4.8 25.9- 31.7 27.8 ± 4.3 25.4- 29.1 0.073
FPG(mg/dl) 104 ± 41 78 -130 86 ± 15 76- 93 86 ± 16 79- 97 0.082
HbA1C (%) 5.9± 1.4 4.8-7.0 5.7 ± 0.7 5.4- 5.9 5.9 ± 0.9 5.5- 6.5 0.794
Insulin( μIU/ml) 26.7 ± 21.0 13.4-39.9 14.2 ± 4.9 11.6- 16.8 16.2 ± 7.6 11.8- 20.6 0.037
HOMAIR 6.4 ± 4.7 3.4- 9.4 3.0 ± 1.2 2.4- 3.7 3.5 ± 1.8 2.5- 4.6 0.01
QUICKI 0.30 ± 0.02 0.29-0.32 0.33 ± 0.02 0.32- 0.34 0.33 ± 0.04 0.31- 0.35 0.016
TG(mg/dl) 267 ± 88 212-323 255 ± 65 219- 286 251 ± 98 197- 312 0.624
TC(mg/dl ) 196 ± 46 167-225 232 ± 52 208- 261 231 ± 48 199- 257 0.066
HDL-C(mg/dl ) 47 ± 10 40-53 48 ± 11 43- 57 55 ± 12 46-58 0.049
LDL-C(mg/dl ) 104 ± 29 86-123 116 ± 29 101- 132 112 ± 30 94- 129 0.478
TG/HDL 6.4 ± 3.3 4.3-8.5 5.5 ± 2.5 4.2- 6.8 5.2± 2.2 3.9- 6.4 0.026
Adiponectin (μg/ml) 6.9 ± 1.6 5.9-8.0 11.2 ± 1.4 10.5- 11.8 18.8 ± 4.5 16.3- 21.4 <0.001
Values are presented as mean ± SD and 95%CI (95% confidence interval). The differences across various parameters of adiponectin tertiles were tested using
ANOVA and least significant difference (LSD) as post hoc tests.BMI: body mass index. HbA1c: hemoglobin A1c. HDL-C: high-density lipoprotein cholesterol. LDL-C:
low-density lipoprotein cholesterol. HOMA-IR: homeostasis model assessment index for insulin resistance. QUICKI: quantitative insulin sensitivity check index.
Takhshid et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:30 Page 5 of 7found that the subjects with TG/GG genotype had a lower
circulating adiponectin concentration. In another study,
Rizk et al. [24] investigated the association of two SNPs of
adiponectin gene (+45 T/G and +276 G/T) and GDM.
The results indicated an association between GG genotype
of SNP +45 T >G and GDM among Arab residents in
Qatar. They also found that there was no difference in
the circulating adiponectin levels between GDM patients
with different genotypes of SNP +45 T >G. Recently,
Beltcheva et al. [23] examined the association of three
common SNPs of adiponectin gene (−11377 C/G, +45 T/
G and +276 G/T) and GDM. The results revealed an asso-
ciation between SNP +276 G/T and GDM, but not with
others. Differences in demographic characteristics, genetic
background, environmental factors and diagnostic criteria
for diagnosis of GDM could account for the inconsistency
among the studies.
Given the fact that SNP +45 T >G is a synonymous mu-
tation (Gly15Gly), the exact molecular mechanisms which
would be responsible for association of SNP +45 T >G
with GDM and T2D are still unknown. A possible mech-
anism is the effects of this silent mutation on expressionTable 4 Genotype and allele frequencies of adiponectin gene
Genotype frequency
group n TT GT/GG
Non GDM 70 54(77.2%) 16(22.8%)
GDM 65 37(56.9%) 28(43.1%)
OR (95% CI), 2.55 (1.21-5.37)
Genotypes are reported as number with percent in parentheses. *Two-tailed chi-sqof ADIPOQ gene and circulating concentration of adipo-
nectin. It has been reported that SNP +45 T >G in the
adiponectin gene could affect the expression of adiponec-
tin by influencing adiponectin mRNA processing or stabil-
ity [21]. It has also been reported that SNP +45 T >G in
the adiponectin gene has an association with circulating
levels of adiponectin [28,30]. However, our results in ac-
cordance with data from other studies [31] showed that
there are no association between circulating level of adi-
ponectin, and SNP +45 T >G genotypes. Linkage disequi-
librium of SNP +45 T >G with other functional SNPs in
the adiponectin gene, particularly SNP +276 G > T, vari-
ation in ethnic background, environmental factors, sample
size and the type of study may account for the discrepan-
cies across studies.
Some previous studies have also found an association
between SNP +45 T > G in the adiponectin gene and
obesity both in healthy individuals and T2D patients
[32,33]. In this study, BMI was used to represent the
degree of obesity. Nevertheless, the data revealed no sig-
nificant association of SNPs +45 and BMI in GDM and
non-GDM subjects. The results were in line with KrizovaSNP T45G in the non –GDM (control) and GDM patients
Allele frequency
p T G p
0.012* 124(88.6%) 16(11.4%) 0.025*
102(78.5%) 28(21.5%)
OR (95% CI), 2.13 (1.09 -4.15)
uare test (χ2). 95%CI = 95% confidence interval.
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be inferred from the literature that differences of race, the
sum of the sample, complicated diseases, etc. would be re-
sponsible for these differences.
Data regarding circulating adiponectin concentration
and its association with metabolic characteristics of
GDM are also controversial. Some previous studies have
found decreased circulating adiponectin concentrations
in the GDM patients than non-GDM control subjects.
Renheim et al. [13] showed lower circulating adiponectin
concentration in the GDM group. Additionally, they
found a reduction in adiponectin mRNA levels in adi-
pose tissue biopsies of GDM subjects. Williams et al.
[14] found that serum adiponectin concentrations were
lower in women with GDM than controls. Furthermore,
they showed that women with low level of serum total
adiponectin (below 6.4 mg/ml) at first trimester of gesta-
tion had increased risk of GDM as compared to pregnant
women with higher concentrations of the adiponectin.
Lain et al. [36] showed that women with hypoadiponecti-
nemia(less than the 25th quartile) were 11 times more
likely to develop GDM, and it continued after controlling
BMI. Kinalski et al. [15] did suggest that hypoadiponecti-
naemia in GDM may reflect impaired glucose metabolism
during pregnancy. Thus, on the basis of the findings, it
has been speculated that reduced adiponectin levels at the
beginning of pregnancy could be considered a risk factor
for development of GDM. In a recent publication on 40
GDM and 40 non-GDM subjects, they showed that
the level of adiponectin in the GDM patients was signifi-
cantly lower in healthy pregnant women at early preg-
nancy (10–12 weeks) than those in late pregnancy (36–38
weeks), and the level of adiponectin was negatively corre-
lated with HOMA-IR. In contrast to the above-mentioned
down-regulated adiponectin levels in GDM, other studies
show unchanged circulating adiponectin levels in patients
with GDM compared to the non-GDM women. Recently,
Saucedo et al. [17], in a case control study performed on
60 GDM and 60 normal glucose tolerance (NGT) con-
trols, demonstrated that circulating adiponectin levels are
similar in both groups although the GDM patients had a
greater insulin resistance than normal pregnant womwn.
Paradisi etal [18] also reported similar findings. They ex-
amined serum concentrations of adiponectin and insulin
resistance in 50 high-risk women at first, second and third
trimesters of pregnancy. They showed a progressive de-
cline of plasma adiponectin levels as the pregnancy ad-
vanced in both normal glucose tolerance (NGT) controls
and GDM subjects; however, values observed in NGT and
GDM subjects were similar. In the current study, circulat-
ing total adiponectin concentration was lower among
GDM subjects although the difference was not statistically
significant. Serum total adiponectin concentration in the
GDM patients negatively correlated with age, HOMA-IR,TG and positively associated with serum HDL cholesterol
concentration. The stepwise multivariate regression ana-
lysis revealed that age and HOMA-ir significantly and
independently contributed to the serum adiponectin values
in patients with GDM. These variables jointly accounted
for 23.3% of the variance. When the patients were classified
into 3 tertile of adiponectin, we observed that those patients
with lower adiponectin had a higher IR (higher HOMA
and lower QUICKI). These inconsistencies could be related
to different criteria for diagnosis of GDM, gestational
age, differences in ethnic backgrounds of the subjects,
and high inter-subject variability in basal adiponectin con-
centration [36,37]. Variation in dietary intakes specifically
magnesium and plant-based foods [10], the methods used
to measure adiponectin, and sample size may also be re-
lated to this discrepancy.
Our study had some limitations. The major limitation
was the relatively small sample size for testing the asso-
ciations of particular SNP with the disease phenotype. In
spite of this limitation, we could detect the association
between SNP +45 G > T of ADIPOQ gene and GDM.
Another limitation was that we tested only one SNP of
ADIPOQ gene that limited the possibilities to examine a
wide range of haplotype combinations. Therefore, fur-
ther investigations with a larger sample size are required
to clarify the impact of SNP +45 T > G in the adiponec-
tin gene on the risk of GDM and different forms of cir-
culating adiponectin with GDM. Finally, in this study,
we considered only the total concentrations of serum
adiponectin while in human plasma, adiponectin circu-
lates in trimeric, hexameric and oligomeric forms which
might be responsible for adiponectin insulin sensitizing
effects [38].
Conclusion
The findings of this study indicated that serum adiponec-
tin was negatively correlated with insulin resistance in
GDM patients. Furthermore, SNP +45 T >G in the adipo-
nectin gene was associated with the susceptibility to GDM
in our population. Further studies are needed to explore
the potential mechanisms by which SNP +45 G > T modu-
lates susceptibility to GDM.
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